• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

    1/7/21 8:00:00 AM ET
    $TRIL
    $PHAT
    $RCKT
    $PASG
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRIL alert in real time by email

    MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.

    Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.

    Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.

    Max Nowicki, M.D., joined the Frazier Life Sciences team in 2019 and focuses on identifying new public and private investment opportunities. He has been involved in numerous Frazier investments, including Rocket Pharmaceuticals (NASDAQ: RCKT) and Trillium Therapeutics (NASDAQ: TRIL).

    “We are thrilled to announce the promotions of Aditya, Anna, and Max,” said James Topper, Managing Partner at Frazier. “They are extremely valuable members of our team, and are instrumental in helping us create new companies, as well as invest in new public and private companies.”

    About Frazier Healthcare Partners

    Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.

    For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

    Get the next $TRIL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRIL
    $PHAT
    $RCKT
    $PASG

    CompanyDatePrice TargetRatingAnalyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    7/25/2025$4.00Buy → Neutral
    BofA Securities
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/30/2025$5.00Outperform → In-line
    Evercore ISI
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025Overweight → Neutral
    Analyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$2.00Neutral → Sell
    Goldman
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$8.00Outperform → Market Perform
    Leerink Partners
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$2.50Buy → Hold
    Jefferies
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$7.00Overweight → Equal-Weight
    Morgan Stanley
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/27/2025Buy → Hold
    TD Cowen
    More analyst ratings

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $662,488 worth of shares (115,725 units at $5.72) and bought $71,338 worth of shares (13,123 units at $5.44) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    7/24/25 6:12:54 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/23/25 4:06:35 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/15/25 4:17:38 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

    SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    8/14/25 8:00:32 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Phathom Pharmaceuticals Inc.

    SCHEDULE 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    8/13/25 4:00:27 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Passage Bio Inc.

    10-Q - Passage BIO, Inc. (0001787297) (Filer)

    8/12/25 7:15:57 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

    Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Submitted amended upliFT-D study protocol to global trial sites and health authorities Cash runway into 1Q 2027 PHILADELPHIA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2025, and provided recent business h

    8/12/25 7:00:00 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

    Prioritizing development of RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM) to advance AAV cardiovascular gene therapy platform for sustained value creation FDA RMAT designation awarded to RP-A601 for PKP2-ACM; Engaging with FDA on pivotal trial design following encouraging initial Phase 1 data at ASGCT IND accepted and FDA Fast Track designation received for RP-A701 in BAG3-DCM program; Phase 1 trial start-up activities underway Organizational restructuring expected to reduce headcount by approximately 30% and lower 12-month cash burn by nearly 25% Chris Stevens appointed Chief Operating Officer Cash, cash equivalents and investments of approximately $271.5M;

    8/7/25 4:00:00 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked

    8/7/25 6:59:20 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals downgraded by BofA Securities with a new price target

    BofA Securities downgraded Rocket Pharmaceuticals from Buy to Neutral and set a new price target of $4.00

    7/25/25 9:00:02 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Rocket Pharmaceuticals from Outperform to In-line and set a new price target of $5.00

    5/30/25 10:04:19 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals downgraded by Analyst

    Analyst downgraded Rocket Pharmaceuticals from Overweight to Neutral

    5/28/25 3:12:28 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Militello John sold $21,263 worth of shares (7,043 units at $3.02), decreasing direct ownership by 11% to 56,984 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    8/18/25 4:35:03 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Schwartz Jonathan David sold $33,695 worth of shares (11,161 units at $3.02), decreasing direct ownership by 5% to 224,094 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    8/18/25 4:35:04 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Wilson Martin sold $36,557 worth of shares (12,109 units at $3.02), decreasing direct ownership by 8% to 137,054 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    8/18/25 4:35:01 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Leadership Updates

    Live Leadership Updates

    View All

    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards to Ms. Cook under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Ms. Cook was granted a non-qualified stock option to purchase

    6/23/25 4:15:00 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NodThera Announces Appointment of Elisabeth Björk as Board Member

    NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

    6/17/25 7:00:00 AM ET
    $PHVS
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Passage Bio Inc.

    SC 13G - Passage BIO, Inc. (0001787297) (Subject)

    11/14/24 12:03:11 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

    SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    11/8/24 10:52:38 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Financials

    Live finance-specific insights

    View All

    Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked

    8/7/25 6:59:20 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

    Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, August 7, 2025, to report its second quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A rec

    7/28/25 8:00:11 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

    Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome. Rocket is conducting a comprehensive root cause analysis and remains in active dialogue with the U.S. Food and Drug Administration (FDA) and other key stakeholders, with the c

    5/27/25 7:00:00 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care